

CORRECTION Open Access



Correction: Benefits of a Juvenile Arthritis Support Program (JASP-1) for children recently diagnosed with Juvenile Idiopathic Arthritis and their parents

Karina Mördrup^{1,2*}, Johanna Granhagen Jungner¹, Eva Broström¹, Karin Palmblad^{1,2} and Cecilia Bartholdson^{1,2}

Correction: BMC Rheumatol 8, 35 (2024)
<https://doi.org/10.1186/s41927-024-00404-8>

Following publication of the original article [1], the authors reported an error in Table 6. “CHAQ/active joints JASP-1 Control group” was mistakenly added to the left column header and should be removed. The published version is

CHAQ/active joints JASP-1 Control group	JASP-1	Control group	
CHAQ	Mean (SD) (n) (95% CI)	Mean (SD) (n) (95% CI)	P-value
At diagnosis	0.68 (0.58) (n=49) (0.51 – 0.84)	0.72 (0.82) (n=12) (0.17 – 1.27)	0.781
At 12 months	0.15 (0.29) (n=48) (0.07 – 0.24)	0.40 (0.54) (n=19) (0.13 – 0.67)	0.017**
Active joints	Mean (SD) (n) (95% CI)	Mean (SD) (n) (95% CI)	P-value

The online version of the original article can be found at <https://doi.org/10.1186/s41927-024-00404-8>.

*Correspondence: Karina Mördrup karina.mordrup@ki.se
¹Department of Women’s and Children’s Health, Karolinska Institutet Neuropediatric Unit, Karolinska vägen 37 A, Solna 171 64, Sweden
²Highly Specialized Pediatric Medicine and Orthopedics, Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden

CHAQ/active joints JASP-1 Control group	JASP-1	Control group	
At diagnosis	5.64 (6.48) (n=53) (3.85 – 7.43)	6.11 (6.48) (n=19) (2.98 – 9.23)	0.624
At 12 months	0.62 (3.47) (n=50) (0.35 – 1.58)	0.87 (1.6) (n=23) (0.18 – 1.59)	0.054*

** Significant
* Close to significant

The correct Table 6 should read:

	JASP-1	Control group	
CHAQ	Mean (SD) (n) (95% CI)	Mean (SD) (n) (95% CI)	P-value
At diagnosis	0.68 (0.58) (n=49) (0.51 – 0.84)	0.72 (0.82) (n=12) (0.17 – 1.27)	0.781
At 12 months	0.15 (0.29) (n=48) (0.07 – 0.24)	0.40 (0.54) (n=19) (0.13 – 0.67)	0.017**
Active joints	Mean (SD) (n) (95% CI)	Mean (SD) (n) (95% CI)	P-value
At diagnosis	5.64 (6.48) (n=53) (3.85 – 7.43)	6.11 (6.48) (n=19) (2.98 – 9.23)	0.624
At 12 months	0.62 (3.47) (n=50) (0.35 – 1.58)	0.87 (1.6) (n=23) (0.18 – 1.59)	0.054*

** Significant
* Close to significant

The original article [1] has been updated.

Published online: 15 January 2025



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Mördrup K, Jungner JG, Broström E, et al. Benefits of a Juvenile Arthritis Support Program (JASP-1) for children recently diagnosed with Juvenile Idiopathic Arthritis and their parents. *BMC Rheumatol.* 2024;8:35. <https://doi.org/10.1186/s41927-024-00404-8>.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.